128 related articles for article (PubMed ID: 20456034)
1. Learning from the pregnane X receptor: how to fight one aggressor with two strategies.
Rust C; Beuers U
Liver Int; 2010 Feb; 30(2):161-3. PubMed ID: 20456034
[No Abstract] [Full Text] [Related]
2. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
3. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
4. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis.
Sasatomi K; Noguchi K; Sakisaka S; Sata M; Tanikawa K
J Hepatol; 1998 Sep; 29(3):409-16. PubMed ID: 9764987
[TBL] [Abstract][Full Text] [Related]
5. Heart and bile acids - Clinical consequences of altered bile acid metabolism.
Vasavan T; Ferraro E; Ibrahim E; Dixon P; Gorelik J; Williamson C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1345-1355. PubMed ID: 29317337
[TBL] [Abstract][Full Text] [Related]
6. Pregnane X receptor activation protects rat hepatocytes against deoxycholic acid-induced apoptosis.
Zucchini-Pascal N; de Sousa G; Pizzol J; Rahmani R
Liver Int; 2010 Feb; 30(2):284-97. PubMed ID: 19737350
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis.
Sakisaka S; Koga H; Sasatomi K; Ohishi M; Kawaguchi T; Harada M; Taniguchi E; Uchimura Y; Ueno T; Sata M; Tanikawa K
Liver; 2000 Feb; 20(1):78-87. PubMed ID: 10726964
[TBL] [Abstract][Full Text] [Related]
8. Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Horiguchi N; Yamazaki Y; Mori M
Front Biosci (Landmark Ed); 2011 Jun; 16(8):2988-3005. PubMed ID: 21622216
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
11. Therapy with ursodeoxycholic acid in cholestatic liver disease.
Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
13. [Cholestasis: therapeutic options].
Beuers U; Oswald M
Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of autoimmune hepatic diseases].
Bueverov AO
Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604
[TBL] [Abstract][Full Text] [Related]
15. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
17. [Cholestasis. Recent diagnostic and therapeutic acquisitions].
Marucci L; Macarri G; Benedetti A
Recenti Prog Med; 2003 Jan; 94(1):19-24. PubMed ID: 12632996
[TBL] [Abstract][Full Text] [Related]
18. [Primary sclerosing cholangitis and primary biliary liver cirrhosis as the causes of intrahepatic cholestasis].
Mandera M; Nowakowska-Duława E; Hartleb M
Wiad Lek; 1992 May; 45(9-10):366-70. PubMed ID: 1441546
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
Serfaty L; Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
[No Abstract] [Full Text] [Related]
20. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
